TFF Pharma, Augmenta Bioworks Select Lead Antibody Program To Develop For COVID-19

  • Augmenta Bioworks and TFF Pharmaceuticals Inc TFFP have selected AUG-3387 as the first lead monoclonal antibody for clinical development against COVID-19 under their joint development Collaboration Agreement. 
  • AUG-3387 will be developed as an inhaled therapy for the treatment of COVID-19 disease.
  • Notably, in in vitro preclinical testing, AUG-3387 effectively neutralizes SARS-CoV2 and has demonstrated activity against all variant strains tested to date. 
  • TFF and Augmenta have an ongoing commitment to monitor the activity of AUG-3387 against emerging variants and will be completing in vivo preclinical efficacy studies in the coming weeks.
  • Price Action: TFFP shares are down 2.98% at $10.09 during the market trading session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralBriefsCovid-19
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!